We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 68.00 | 0.56% | 12,118.00 | 12,120.00 | 12,124.00 | 12,162.00 | 11,966.00 | 11,966.00 | 2,181,317 | 16:35:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.56 | 187.91B |
From May 2021 to May 2024
By Michael Dabaie
Aridis Pharmaceuticals Inc. said it is an exclusive licensing agreement with AstraZeneca for late stage monoclonal antibody candidate suvratoxumab.
The company said it acquired the global exclusive rights for development and commercialization of suvratoxumab for all indications.
Aridis said it licensed phase 3-ready candidate suvratoxumab for prevention of pneumonia and suvratoxumab would extend its pneumonia franchise by complementing its existing AR-301 Phase 3 pneumonia treatment program.
Aridis said it will make an upfront payment to AstraZeneca of $11 million in cash and Aridis common stock. AstraZeneca will also receive up to a further $115 million for development and sales-related milestones, in addition to tiered royalties on net sales.
The EU Commission's Innovative Medicines Initiative COMBACTE clinical trial consortium will give up to 25 million euros, or about $30 million, for the Phase 3 trial for suvratoxumab.
AstraZeneca will become a shareholder of Aridis through the stock issuance and has right of first negotiation for future licensing of suvratoxumab.
Aridis shares rose 1% to $5.90 in premarket trading.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 19, 2021 09:19 ET (13:19 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
